Sangamo Therapeutics, Inc. (SGMO) Financial Analysis & Valuation | Quarter Chart
Sangamo Therapeutics, Inc. (SGMO)
SGMOPrice: $0.25
Fair Value: 🔒
🔒score
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP)... more
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science i... more
Description
Shares
| Market Cap | $91.77M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Alexander D. Macrae Ch.B |
| IPO Date | 2000-04-06 | CAGR | 0.15% |
| Employees | 183 | Website | www.sangamo.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.02% | Total Yield | 0.02% |
SGMO chart loading...
Fundamentals
Technicals
| Enterprise Value | $145.99M | P/E Ratio | -0.84 |
| Forward P/E | inf | PEG Ratio | — |
| P/S Ratio | 2.32 | P/B Ratio | -5.84 |
| P/CF Ratio | -0.86 | P/FCF Ratio | -0.94 |
| EPS | $-0.45 | EPS Growth 1Y | -15.19% |
| EPS Growth 3Y | -64.98% | EPS Growth 5Y | -52.98% |
| Revenue Growth 1Y | -31.57% | Gross Margin | 0.64% |
| Operating Margin | -3.07% | Profit Margin | -3.11% |
| ROE | -29.83% | ROA | -2.06% |
| ROCE | -7.02% | Current Ratio | 0.84 |
| Quick Ratio | 0.84 | Cash Ratio | 0.49 |
| Debt/Equity | -1.76 | Interest Coverage | — |
| Altman Z Score | -43.46 | Piotroski Score | 1 |